Gain Therapeutics Shares Outstanding History (GANX)
Gain Therapeutics reported 42.1M shares outstanding at the end of fiscal 2025.
View full Gain Therapeutics company overviewGain Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 42.1M | 14.9M | +55.07% |
| 2024 | 2024-12-31 | 27.1M | 10.9M | +67.42% |
| 2023 | 2023-12-31 | 16.2M | 4.3M | +36.38% |
| 2022 | 2022-12-31 | 11.9M | 0 | 0.00% |
| 2021 | 2021-12-31 | 11.9M | 8.3M | +235.39% |
| 2020 | 2020-12-31 | 3.5M | — | — |
Gain Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 43.3M | 12.6M | +40.85% |
| Q1 2026 | 2026-03-31 | 42.5M | 13.7M | +47.81% |
| Q4 2025 | 2025-12-31 | 42.1M | 14.9M | +55.07% |
| Q3 2025 | 2025-09-30 | 36.0M | 10.0M | +38.57% |
| Q2 2025 | 2025-06-30 | 30.8M | 5.6M | +22.24% |
| Q1 2025 | 2025-03-31 | 28.7M | 10.7M | +59.34% |
| Q4 2024 | 2024-12-31 | 27.1M | 10.9M | +67.42% |
| Q3 2024 | 2024-09-30 | 26.0M | 13.2M | +103.10% |
| Q2 2024 | 2024-06-30 | 25.2M | 12.5M | +99.27% |
| Q1 2024 | 2024-03-31 | 18.0M | 6.0M | +49.26% |
| Q4 2023 | 2023-12-31 | 16.2M | 4.3M | +36.38% |
| Q3 2023 | 2023-09-30 | 12.8M | 899,493 | +7.57% |
| Q2 2023 | 2023-06-30 | 12.6M | 748,959 | +6.30% |
| Q1 2023 | 2023-03-31 | 12.1M | 203,774 | +1.71% |
| Q4 2022 | 2022-12-31 | 11.9M | 0 | 0.00% |
| Q3 2022 | 2022-09-30 | 11.9M | 3,625 | +0.03% |
| Q2 2022 | 2022-06-30 | 11.9M | 6,908 | +0.06% |
| Q1 2022 | 2022-03-31 | 11.9M | 6,908 | +0.06% |
| Q4 2021 | 2021-12-31 | 11.9M | 4.2M | +54.44% |
| Q3 2021 | 2021-09-30 | 11.9M | — | — |
| Q2 2021 | 2021-06-30 | 11.9M | — | — |
| Q1 2021 | 2021-03-31 | 11.9M | — | — |
| Q4 2020 | 2020-12-31 | 7.7M | — | — |
Gain Therapeutics shares outstanding trends
Over the last five reported fiscal years, Gain Therapeutics's shares outstanding moved from 3.5M to 42.1M, a change of 38.5M. The latest reported quarter, Q2 2026, shows 43.3M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gain Therapeutics filings at SEC.gov ↗